XRAY Stock Recent News
XRAY LATEST HEADLINES
Investors need to pay close attention to XRAY stock based on the movements in the options market lately.
XRAY's EDS and Wellspect are the key to stabilizing their results going forward. OIS and CTS continue to decline, but SureSmile grows in Europe. Their new CEO will also prioritize execution, rather than reinventing XRAY. They'll double down on integrated digital workflows and better customer experience. If they build a stickier ecosystem, I think XRAY does have the potential for a turnaround.
Explore Dentsply's (XRAY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY ) Q2 2025 Earnings Call August 7, 2025 8:30 AM ET Company Participants Andrea Daley - Vice President of Investor Relations Daniel T. Scavilla - President, CEO & Director Matthew E.
DENTSPLY SIRONA tops Q2 earnings estimates with margin gains, but revenue declines and U.S. weakness persists.
The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dentsply International (XRAY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.49 per share a year ago.
CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2025.
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Dentsply International (XRAY) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?